drugset / Trial / NCT00996333
Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to determine whether an investigational drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer.
Timeline
- Start
- 2003-06
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1500 mg/m2 | Oral |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 750 mg/m2 | Intravenous |